Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.06.
Durvalumab na chemoradiotherapie bij stadium III niet-kleincellig longcarcinoom
aug 2018 | Longoncologie